The androgen receptor (AR) has a critical role in the development and progression of prostate cancer (PC) and is a major therapeutic target in this disease. The transcriptional activity of AR is modulated by the coregulators with which it interacts, and consequently deregulation of cofactor expression and/or activity impacts the expression of genes whose products can have a role in PC pathogenesis. Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. Conversely, ELF3 knock down increases the AR transcriptional activity. Biochemical dissection of this activity indicates that it results from the physical interaction between ELF3 and AR and that this interaction inhibits the recruitment of AR to specific androgen response elements within target gene promoters. Significantly, we observed that depletion of ELF3 expression in LNCaP cells promotes cell migration, whereas increased ELF3 expression severely inhibits tumor growth in vitro and in a mouse xenograft model. Taken together, these results suggest that modulation of ELF3 expression and/or AR/ELF3 interaction may have utility in the treatment of PC.
INTRODUCTION
The androgen receptor (AR) is a member of the nuclear hormone receptor superfamily of ligand-regulated transcription factors. The role of AR in benign hyperplasia and malignancy of the prostate is well established and has provided substantial validation for AR as a therapeutic. 1, 2 Prostate cancer (PC) affects one in six men during their lifetime and is second only to lung cancer as a cause of cancer death in males. 3 Although surgical intervention is very effective in eradicating localized disease, chemical androgen ablation therapies such as administration of gonadotropin releasing hormone agonists and/or AR antagonists are still the most successful treatment options for patients with metastatic PC. Unfortunately, patients who have undergone androgen ablation therapy often develop resistance and progress to a hormonerefractory state, beyond which point drugs targeting the androgen axis have limited clinical utility. 4 Despite being refractory to androgen ablation therapy, studies in human biopsies as well as in xenograft models have suggested that AR remains transcriptionally active (or is re-activated) in late-stage disease. Several mechanisms have been proposed to explain the process by which cancers progress to a hormone-refractory state, including AR mutations, amplification and/or increases in local androgen production. [5] [6] [7] In addition, it has been shown that deregulation of cofactor expression or activity can, in certain circumstances, permit weak androgens and anti-androgens to activate those AR target genes responsible for cell growth, leading ultimately to the development of hormone-refractory PC. [8] [9] [10] [11] [12] [13] [14] AR can either stimulate or repress gene transcription, an activity that is determined by promoter context, cofactor availability and the impact of different signaling pathways on the functionality of receptor-cofactor complexes. A large number of AR-interacting proteins have been identified to date, although the physiological and pathological significance of all but a few remains to be determined. 11 Cofactors can modulate AR action by (a) regulating chromatin remodeling or histone modification, (b) serving as bridging elements between the receptor and DNA or with the basal transcriptional machinery, or (c) by physically interfering with the interaction of the receptor with the transcription apparatus. Not surprisingly, it has been shown that the biological endpoints resulting from the activity of different AR-cofactor complexes are not equivalent, suggesting that pharmaceuticals that are able to differentially modulate specific receptorcofactor interactions are likely to have distinct biological activities.
E74-like factor 3 (ELF3, also known as ESE-1) is a member of the ETS family of transcription factors. 15, 16 Members of the ETS family have crucial roles in several biological processes, including the regulation of cell differentiation, hematopoiesis, angiogenesis as well as cartilage and skeletal development. 17 Like most transcription factors, ETS proteins can either activate or repress gene transcription depending on the cell and promoter context in which they operate. Gene knockout studies have shown that ELF3 has essential roles during development and, in the adult, it is expressed in organs that contain secretory epithelial cells such as the lung, kidney, liver, pancreas, gastrointestinal tract, prostate and the mammary gland. 15, 16, 18 Genes shown to be regulated by ELF3 are involved in inflammation, differentiation, tumorigenesis and metastasis. 17 Cooperative interactions between ELF3 with other transcription factors such as nuclear factor-kB, SP1 (specificity protein 1) and AP-1 (activator protein 1) have been reported by other groups. 19, 20 Although ELF3 has been implicated in cancer, most studies performed to date have focused on defining its role in breast cancer pathogenesis. [21] [22] [23] [24] Although a specific role for ELF3 in PC has not been reported, chromosomal translocations that result in fusions between the ETS family members ETV1, ERG, ETV4 and TMPRSS2 are found in a majority of advanced PCs. 25, 26 It was of interest therefore that we recently identified ELF3 as a potential AR-interacting protein. 27 Following up on this finding, we determined that ELF3 is indeed a bona fide coregulator functioning as a negative modulator of AR transcriptional activity. Furthermore, manipulation of ELF3 inhibits androgen-dependent growth and migration of PC cells. These findings highlight the biological significance of the AR/ELF3 interaction in PC biology and suggest that this complex may be a target for novel therapeutic interventions.
RESULTS
Interaction between ELF3 and the AR Previously, we reported the results of a high-throughput proteinprotein interaction screen that used T7 phage display technology to identify proteins that interacted either directly or indirectly with AR in the presence of different ligands. Over 300 interacting proteins were identified in this manner the functional significance of which remain under investigation. 27 Among the proteins that were identified in this manner was ELF3, a member of the ETS family of transcription factors, a class of proteins that have been implicated in the pathology of solid tumors. 17 Furthermore, we utilized paired-sample data from GSE21034 28 to demonstrate in a case-by-case manner that the expression of ELF3 is downregulated in a subset of primary prostate tumors when compared with expression in normal adjacent sites (Figure 1a) . Consequently, we proceeded to evaluate the possibility that ELF3 was a biologically relevant regulator of AR action in the prostate. As a first step in this process, we performed a co-immunoprecipitation (CoIP) assay to demonstrate an interaction between endogenous ELF3 and AR in LNCaP cells. As shown in Figure 1b , ELF3 was detected in cell lysate immunoprecipitated with AR antibody. In addition, AR was also detected in cell lysate subjected to immunoprecipitation with ELF3 antibody. Interestingly, the interaction was significantly enhanced in the presence of R1881. Subsequently, in vitro glutathione S-transferase (GST) pull-down assays were used to show that recombinant AR and ELF3 interact directly and to define the domains within each protein that were required for the observed interaction. To this end, purified full-length GST-ELF3 was incubated with either in vitro translated full-length AR or fragments thereof encoding selected functional Figure 1c . The results of this analysis confirm that the two proteins can directly interact with each other, albeit weakly, and that both the amino-and carboxy-terminal domains of AR bind to ELF3. Furthermore, it was demonstrated that Flag-ELF3 co-localizes with AR in the nuclei of LNCaP cells following the addition of R1881 (Figure 1d ). In summary, the results of these protein-protein interaction assays performed in vitro and within intact cells imply the existence of a close physical association between ELF3 and AR, a finding that encouraged us to explore the functional consequences of this association.
ELF3 represses AR-dependent transcriptional activity To address the functional role of ELF3 in AR signaling, we first evaluated the impact of its expression on AR transcriptional activity in androgen-responsive reporter gene assays in HEPG2 and LNCaP cells, respectively. In the AR-negative HEPG2 cells, transfection of an AR expression plasmid leads to robust R1881-dependent activation of of the synthetic promoter containing two sets of Androgen Response Element 2XARE-luciferase, prostate-specific antigen (PSA)-luciferase and mouse mammary tumor virus (MMTV)-luciferase reporter genes (Figure 2a ). Cotransfection of ELF3 dramatically inhibits the AR-dependent activation of both the 2XARE-and PSA-luciferase reporters. Minimal but significant inhibition of the MMTV-luciferase reporter was also observed in this assay. Similarly, ELF3 expression in LNCaP cells reduces the transcriptional activity of endogenous AR on the PSA, KLF5 and MMTV-luciferase reporter genes ( Figure 2b ). However, ectopic expression of ELF3 did not change AR protein levels in both the HepG2 and LNCaP cells as shown by western blot (Figures 2a and b) . Importantly, ELF3 inhibitory activity was noted at all concentrations of R1881 and its ability to repress the activity of the PSA promoter in HEPG2 cells expressing AR cannot be reversed by increasing doses of R1881 (Figure 2c ). We next examined the activity of ELF3 in the presence of the AR antagonist Casodex (CSX) on AR transcriptional activity using the PSA reporter gene assay in HEPG2 cells ( Figure 2d ). As expected, treatment with CSX blocked the R1881 induction of PSA promoter activity in control-transfected cells. Interestingly, a greater level of repression of the PSA promoter activity by CSX was observed in the presence of ELF3, a result that is consistent with ELF3 acting as an AR corepressor.
Identification of the domains within ELF3 required for AR repression
In an effort to define the mechanism(s) by which ELF3 impacts AR transcriptional activity we used a series of mutations to define the functions of this protein that are required for repression. ELF3 contains five distinct domains: (1) a pointed domain (PNT), which has been implicated in protein-protein interactions, (2) a transactivation domain (TAD), (3) a serine-and aspartic acid-rich (SAR) domain, which influences cellular transformation, (4) an AT-hook domain suggested to be involved in non-sequence-specific binding to AT-rich regions of DNA and in protein-protein interactions, and (5) an ETS domain, which is required for DNA binding ( Figure 3 ). To examine the role of each of these domains in AR repression, we used a series of expression constructs that encoded ELF3 proteins in which the integrity of these domains was disrupted and assayed their activity in HepG2 cells in which AR was co-expressed ( Figure 3 ). In fact, expression of the ETS domain alone (DN270) acts as a dominant-negative inhibitor of wild-type ELF3 activity and reproducibly increases AR activity by more than twofold in this assay. In agreement with these results, disruption of the ahelices within the ETS domain, (A312P) and (I279P) point mutations also disrupted ELF3-mediated repression of PSA promoter activity. The role of the A/T hook domain in this process is more complex in that deletion of one hook motif (D237-241) abolishes ELF3 repression activity, while simultaneous deletion of both motifs (D235-260 and D237-241 þ D246-250) only partially impairs the repressor function of ELF3. Introduction of the point mutation, L143P, a manipulation shown previously to disrupt the TAD function of ELF3, 29 reduces its repressor activity by 40%. It has been shown that the regions flanking the ETS ELF3 inhibits androgen action A Shatnawi et al domain within the ETS1 or ETS2 proteins regulate their ability to bind to DNA. 30 Removal of the C-terminal tail of ELF3 (D355-362) significantly reduces the ability of ELF3 to repress AR activity. This finding is of particular importance as the original T7-derived fragment of ELF3 that interacted with AR contains this domain alone, suggesting that the ability of ELF3 to interact with DNA may contribute to its AR-inhibitory activity.
AR target genes regulation following knock down or overexpression of ELF3 To further investigate the functional role of ELF3 on AR action in an endogenous setting, the expression of a series of wellcharacterized AR-regulated genes were assessed in LNCaP cells following ELF3 knock down. For these studies, two separate siRNAs (siELF3#1 and siELF3#2) that target the coding region of ELF3 were used to knock down the expression of endogenous ELF3. A scrambled siRNA (siC) was used as a negative control in these knockdown experiments. In addition, for comparison, we also included in these experiments an siRNA directed against AR (siAR). Introduction of either siELF3#1 or siELF3#2 results in an efficient knock down of ELF3 protein expression (Figure 4a ) and an increase in AR-target gene expression in LNCaP cells (Figure 4b ). This is particularly evident for genes whose induction was modestly but significantly induced upon activation of AR by R1881 that is, NDRG1, SLC16A6, NKX3.1 and SLC45A3. To examine the effect of ELF3 overexpression on AR function, lentiviruses were constructed that utilized the doxycycline (Dox)-inducible pLVX-TetOn system to conditionally express ELF3 at different levels in stably transfected LNCaP cells. Western blot analysis was used to confirm that ELF3 expression could be upregulated in these cells following Dox addition (Figure 4c ). Importantly, we observed that the expression of all R1881-induced AR target genes examined was significantly reduced, albeit to a different degree, in cells expressing ELF3 (Figure 4d) . (Figure 4e) . A ChIP assay using an antibody against the FLAG epitope failed to detect exogenous FLAG-tagged ELF3 at these AR-binding sites, further suggesting that ELF3 inhibits AR function by interfering with its ability to interact with DNA ( Figure 4e ). To confirm whether the repressive function of AR by ELF3 is through a direct protein-protein interaction and not by competing with AR recruitment to its DNA elements on its target genes, LNCaP cells were transiently transfected with either I279P or A312P ETS point mutation constructs and subjected to a ChIP assay (Supplementary Figure S1) . Interestingly, point mutations within ELF3 DNA-binding domain did not block AR recruitment to AREs within the PSA, NKX3.1 and TMPRSS2 genes in R1881-treated cells, suggesting that repression of AR function by ELF3 does not involve competition for DNA binding. This finding is consistent with our observation that the ETS domain when expressed on its own acts as a dominant-negative inhibitor.
ELF3 depletion increases androgen-dependent migration of PC cells and ectopic expression of ELF3 inhibit cell proliferation in vitro AR has been shown to have a critical role in PC cell migration. To assess the potential role of ELF3 in this process, LNCaP PC cells were transfected with either of two siRNAs targeting ELF3, and the impact of this manipulation on migration was evaluated. As expected, addition of R1881 increased LNCaP cell migration, and this activity was not affected by a control siRNA. However, introduction of the siRNAs targeting ELF3 led to a significant increase in LNCaP cells migration (Figures 5a and b) . Further, to explore the effect of ELF3 ectopic expression on PC proliferation, TetOn-Flag-ELF3-LNCaP cells were grown in CS-RPMI1640 and subjected to a proliferation assay using xCELLigence technology from Roche Diagnostics (Indianapolis, IN, USA) ( Figure 5c ). As predicted, R1881 treated cells showed an increase in LNCaP cell proliferation. Conversely, the induction of ELF3 expression by Dox abrogates the proliferation of LNCaP cells treated with R1881.
ELF3 expression inhibits PC cell growth in a xenograft model of PC To examine the biological function of ELF3 in PC in vivo, the TetOn-Flag-ELF3-LNCaP cell line (described above) was propagated as a xenograft in mice. Cells were injected subcutaneously into the right flank of non-castrated SCID male mice and assigned into two groups, one fed with Dox-containing diet to induce ELF3 expression and the other fed with a regular diet. As shown in Figure 6a , tumors grew significantly faster in control compared with the Dox-induced group. The growth velocity of the tumors in the control group was significantly higher than in the Dox-fed group, and the average tumor weight at the end of the experiment in control was also higher when compared with tumors that were grown in mice fed Dox (Figure 6b) . Importantly, overexpression of ELF3 did not affect the expression levels of AR (Figure 6a, inset) . However, the expression of selected AR target genes was inhibited in the ELF3-expressing tumors (Figure 6c) . Cumulatively, these findings highlight the functional importance of ELF3 in PC pathogenesis.
DISCUSSION
The androgen-signaling axis is a primary target for therapeutics used for the treatment of advanced PC. Although most of these drugs function by directly interfering with AR function, it has become clear of late that approaches that target the expression and/or activity of AR coregulators may also yield useful pharmaceuticals. 31 There is, therefore, a considerable amount of interest in identifying those coregulators that are essential for androgen action in PC and in follow-on studies, which evaluate the likely impact of interfering with these factors on processes of pathological importance in cancer. Thus, in this study, we have undertaken a biochemical and genetic approach to define the role of the AR-interactor, ELF3, a member of the ETS family of transcription factors, on AR signaling and on PC pathology.
The majority of PCs have been shown to express at least one gene fusion comprised of an ETS family member together with an AR target gene. Why these particular fusions dominate over others in this disease is unclear, but it may relate to the high transcriptional activity of AR target genes in PC. Regardless, the high prevalence of ETS proteins in these fusions suggests that dysregulation of the activity of transcription factors in this class contributes to cancer pathogenesis. The functional relationship between AR and the ETS proteins was further substantiated by studies, which demonstrated that overexpression of AR and the ETS factor ERG in murine prostate facilitates the development of invasive adenocarcinoma. 26, 32 Furthermore, using ChIP-chip and ChIP-seq approaches, it was determined that ETS-binding sites were enriched near sites of AR-occupancy, and indeed, direct co-occupancy of AR and ERG at regulatory sequences was observed on 44% of target genes. In agreement with these observations, ERG was found to interact directly with AR through its ETS domain, but the mechanism(s) that enable these proteins to bind in a cooperative manner to DNA remain elusive. 33 A functional role for ERG as a corepressor was highlighted by studies, which revealed that its overexpression in PC cells resulted in the inhibition of the expression of AR responsive genes associated with differentiation to which binding sites for this transcription factor had been mapped. Here we show that ELF3, like ERG, inhibits AR signaling. However, the molecular mechanisms underlying the functional antagonism between ELF3 and AR signaling are distinct. Of note, we have determined that the physical interaction of ELF3 with AR blocks the interaction of the receptor with its regulatory sequences in target genes. Not surprisingly, therefore, in contrast to what was described for ERG, co-occupancy of AR and ELF3 at AR target genes was not observed in our studies. Together, these findings reveal that the mechanisms by which the ETS proteins impact AR function are different; a finding that may reflect their different roles in AR action in the normal prostate and in PC.
The currently available antiandrogens work by competitively blocking agonist binding to the receptor and inducing a conformational change that (a) prevents the intramolecular interaction between the amino and carboxyl termini of AR and (b) disrupts the interaction of AR with its attendant cofactors. 8 In addition, the specific conformational change induced by the most efficacious antiandrogens, MDV3100 and ARN509, reduce the affinity of AR for DNA. 34 Thus, subtle differences in the structure of an AR ligand can facilitate functionally important alterations in the conformation of AR and results in the preferential recruitment of corepressors. 27 Key to the development of such compounds is the ELF3 inhibits androgen action A Shatnawi et al identification and characterization of those AR-corepressors that are expressed in PC cells. The studies presented in this paper highlight the potential utility of developing compounds that enable a robust interaction of AR with ELF3. Given the dramatic effect of ELF3 overexpression on the growth of prostate tumors in vivo and on cell migration in vitro, it is anticipated that compounds that facilitate AR/ELF3 interactions would have useful therapeutic activity in PC. These data also highlight the potential of compounds that increase ELF3 expression and effect an inhibition of AR activity in an indirect manner. In summary, ELF3 is an AR-interacting corepressor the disruption of which results in enhanced AR signaling in PC and whose overexpression significantly impedes the androgen-dependent growth of PC xenografts. A role for this protein in AR action has not been contemplated previously, although our studies highlight its importance in PC pathogenesis.
MATERIALS AND METHODS
Chemicals and reagents and antibodies DMEM (Dulbecco's modified Eagle's medium), MEM (Minimum Essential Medium), RPMI-1640, LipofectAMINE 2000, Opti-MEM-reduced serum medium, fetal bovine serum (FBS), nonessential amino acids (NEAA), sodium pyruvate (NaPyr) and the penicillin/streptomycin/L-glutamine stock mix, anti-mouse antibody coupled to Alexa-555 and the anti-rabbit antibody coupled to Alexa-488 were purchased from Invitrogen (Carlsbad, CA, USA). Methyltrienolone (R1881) was purchased from PerkinElmer (Waltham, MA, USA). Bicalutamide (CSX), G418, fatty acid-free BSA, puromycine and anti-Flag M2 antibody were purchased from Sigma (St Louis, MO, USA). Dox and Tet-system-approved FBS were purchased from Clonetech (Mountain View, CA, USA). Luciferase assay reagents were from Promega (Madison, WI, USA). Custom oligonucleotide primers were from IDT (San Diego, CA, USA). The reagents for quantitative real-time reverse transcriptase-PCR were from Roche Diagnostic. AR (N-20)X was from Santa Cruz biotechnology (Santa Cruz, CA, USA). ELF3 antibody was from Epitomics (Burlingame, CA, USA) and V5-tag antibody was from Abcam (Cambridge, MA, USA).
Plasmids CMV-bgal, PGL4.26, pcDNA3.1-ARwt, pSG5-AR, PSA-Luc, KLF5-Luc, MMTV-Luc and 2XARE-Luc constructs have been previously described. 35 Mouse pcDNA-Flag-ELF3 construct, its deletions and mouse GFP-point mutations were a generous gift from Dr Angie Rizzino (University of Nebraska Medical Center) and previously described in Kopp et al. 36 The mouse Flag-ELF3 (I279P) and Flag-ELF3 (A312P) mutants were generated by subcloning of the ELF3 cDNA of GFP-ELF3 (I279P) and GFP-ELF3 (A312P) obtained above into the pcDNA3-Flag-SV40/NLS vector. pcDNA-nV5-ELF3 was generated by sublconing of the human ELF3 cDNA clone #3537846 obtained from ATCC (Manassas, VA, USA) into pcDNA-nV5 vector. The pcDNA-nV5-ELF3 Western blot analysis, preparation of cell lysates and luciferase assay
Western blots were performed as previously described. 37 Luciferase assays were also performed as described. 35 For luciferase assays, each treatment was performed in triplicate. Results are expressed as mean ± s.d. Experiments were repeated at least three times with a representative experiment shown.
Immunofluorescence and confocal microscopy LNCaP cells were plated at density (3 Â 10 5 ) per well onto coverslips in sixwell plates in phenol-free charcoal-stripped CS-RPMI-1640 medium and transfectd with Flag-ELF3 plasmid using LipofectAMINE 2000. Forty-eight hours later, the cells were treated with either R1881 or vehicle for additional 16 h, and the immunoflurecenese was performed as described previously. 38 CoIP and GST pull-down assay LNCaP cells were plated in CS-RPMI1640 media for 48 h. Then the cells were treated with either vehicle or R1881 for additional 24 h. At the endpoint, the whole-cell lysate was extracted and subjected to CoIP as described. 39 For the GST pull-down assay, the GST and full-length ELF3-GST fusion proteins, radioactive AR full-length or truncated proteins were prepared and subjected to pull-down assay as previously described. 39 RNA isolation, cDNA preparation, and quantitative reverse transcriptase-PCR RNA isolation, cDNA preparation and quantitative PCR were performed as previously described in ref. 35 . Reverse and forward primers are listed in (Supplementary Table S1 ). All samples were assayed in triplicate and normalized to an internal control RPLP0.
ChIP assays AR ChIP assays were performed as described previously. 40 Antibody for AR (N-20)X and anti-FLAG M2 were used for ChIP. The forward and reverse primers used for the various target sequences in the ChIP assays are shown in (Supplementary Table S1 ). The intensity of the enrichment signals was normalized to a non-ARE negative control region.
Inducible TetOn-Flag-ELF3 LNCaP stable cell line Lentiviruses derived from the pLVX-TetOn advanced system vectors were purchased from Clonetech were used to stably manipulate the expression of Flag-ELF3 in LNCaP cells. The 293T packaging system was used to generate the viruses, and the resulting purified Lentiviruses were used to infect LNCaP cells. Sequential infection was used to generate the cell line ELF3 inhibits androgen actionneeded for this study. The first round of infection was used to generate the LNCaP cells that constitutively express the tetracycline-controlled transactivator by infecting the cells with viruses carrying pLVX-TetOn expression vector. Then the recombinant cells were selected using 0.8 mg/ml G418. The cells were exposed to a second round of infection with viruses expressing Flag-ELF3 cloned into a pLVX-Tight-Puro vector and selected with puromycine 2 mg/ml. The new cell line was maintained in antibiotic G418 and puromycine containing media. Protein and mRNA expression levels of ELF3 were confirmed by western blot and quantitative PCR analysis, respectively, in the presence and the absence of Dox treatment at 2 mg/ml.
Migration assays and siRNA transfection of cultured human prostate cell lines LNCaP cells were plated and transfected with siRNAs against ELF3, AR coding sequences or siRNA control (siC). The siRNA transfection and migration assay was performed as described previously. 35 The siRNAs sequence list is shown in Supplementary Table S1 .
Proliferation assay
Proliferation assay was done by Roche DP real-time cell analyzer xCELLigence technology. TetOn-Flag-ELF3 LNCaP cells were grown in phenol-free CS-RPMI 1640 medium. Forty-eight hours later, the cells were treated with ±Dox and with either vehicle or R1881 as indicated for additional 24 h. Background impedance was determined after incubating the E16-plates with 100 ml of CS-RPMI 1640 medium for 30 min at room temperature. Then the cells were plated in E16-plate at 2 Â 10 4 cells per well and continued the treatments with ±Dox and with either vehicle or R881, and then placed in the xCELLigence machine for additional 50 h. The Delta Cell Index for each time point (DCI ti ) was measured every 1 h. DCI ti was calculated as the cell index (CI ti ) at a given time point plus a Delta value. The Delta value is the difference between a DCI reference value ( ¼ 1) and the cell index at the Delta time point as follows: DCI ti ¼ CI ti þ (1 À CI Delta_time ). Delta Time point (CI Delta_time ) was set at 5 h, a time point following cell adherence but before cell proliferation.
Murine tumor xenograft model NOD.CB17-Prkdc
scid /J non-castrated SCID male mice 4-weeks old were purchased from Jackson Laboratories (Bar Harbor, ME, USA). After a 1-week period of acclimation, the mice were injected with 6 Â 10 6 TetOn-Flag-ELF3 LNCaP suspended in 200 ml of a 50% mixture containing RPMI 1640 medium and Matrigel matrix basement membrane (BD Corporation, Bedford, MA, USA) subcutaneously into the right flank region. The mice were either fed with Dox (200 mg/kg)-containing diet (BioServ, NJ, USA) to induce the ELF3 expression or with a control regular diet. The sizes of the resultant tumors were measured weekly. At endpoint, the tumors were harvested surgically, flash-frozen for RNA and protein extraction.
Statistical analysis
Results are presented as mean ± s.d. The significance of statistical differences (P-values) between the indicated groups in each experiment was determined using Student's t-test and analysis of variance. Asterisks represent P-value p0.05 unless otherwise indicated.
